skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Yttrium Y 90 Daclizumab (Code C2600)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Yttrium Y 90 Daclizumab

Definition: A synthetic radioimmunoconjugate comprised of a humanized anti-interleukin-2 (IL-2) antibody linked to the radioisotope Yttrium 90 with potential antineoplastic activity. Daclizumab binds with high affinity to the Tac (also called CD25) subunit of the IL-2 receptor complex and inhibits the binding of IL-2, thereby blocking the IL-2-mediated activation of lymphocytes. As Yttrium Y 90 daclizumab, daclizumab delivers radiation specifically to lymphocytes that express the IL-2 receptor. (NCI04)

Display Name: Yttrium Y 90 Daclizumab

Label: Yttrium Y 90 Daclizumab

NCI Thesaurus Code: C2600 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0935688  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Y90 Daclizumab
Y90 MOAB Anti-Tac
Yttrium Y 90 Daclizumab

External Source Codes: 
PDQ Closed Trial Search ID 38097
PDQ Open Trial Search ID 38097 (check for NCI PDQ open clinical trial info)
UMLS CUI C0935688

Other Properties:
     Name Value (qualifiers indented underneath)
code C2600
Contributing_Source CTRP
Legacy_Concept_Name Yttrium_Y_90_Daclizumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom